Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNX NASDAQ:NAMS NYSE:OGN NASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$34.12+1.9%$37.40$25.83▼$57.99$3.58B0.241.22 million shs355,972 shsNAMSNewAmsterdam Pharma$30.73-0.7%$33.52$17.63▼$42.21$3.58B0.071.01 million shs518,477 shsOGNOrganon & Co.$13.41+0.1%$11.01$5.69▼$13.48$3.52B1.557.27 million shs1.01 million shsOLMAOlema Pharmaceuticals$10.31+3.5%$14.30$3.89▼$36.26$898.66M1.981.42 million shs441,757 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+1.70%-3.01%-10.67%-10.36%+1.42%NAMSNewAmsterdam Pharma-1.81%-2.64%-20.09%-1.02%+53.67%OGNOrganon & Co.-0.07%+0.15%+0.30%+107.04%+40.01%OLMAOlema Pharmaceuticals-3.39%-21.64%-33.15%-36.80%+123.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$34.12+1.9%$37.40$25.83▼$57.99$3.58B0.241.22 million shs355,972 shsNAMSNewAmsterdam Pharma$30.73-0.7%$33.52$17.63▼$42.21$3.58B0.071.01 million shs518,477 shsOGNOrganon & Co.$13.41+0.1%$11.01$5.69▼$13.48$3.52B1.557.27 million shs1.01 million shsOLMAOlema Pharmaceuticals$10.31+3.5%$14.30$3.89▼$36.26$898.66M1.981.42 million shs441,757 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+1.70%-3.01%-10.67%-10.36%+1.42%NAMSNewAmsterdam Pharma-1.81%-2.64%-20.09%-1.02%+53.67%OGNOrganon & Co.-0.07%+0.15%+0.30%+107.04%+40.01%OLMAOlema Pharmaceuticals-3.39%-21.64%-33.15%-36.80%+123.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.90Moderate Buy$76.13123.11% UpsideNAMSNewAmsterdam Pharma 2.83Moderate Buy$48.6058.15% UpsideOGNOrganon & Co. 1.71Reduce$11.40-14.96% DownsideOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.10327.74% UpsideCurrent Analyst Ratings BreakdownLatest OLMA, CRNX, NAMS, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026OLMAOlema Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/15/2026OGNOrganon & Co. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/13/2026OLMAOlema Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $35.005/11/2026CRNXCrinetics Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$87.00 ➝ $84.005/8/2026CRNXCrinetics Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$97.00 ➝ $95.004/29/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$12.00 ➝ $14.004/28/2026CRNXCrinetics Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$96.00 ➝ $97.004/28/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2026OGNOrganon & Co. Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$5.00 ➝ $14.004/21/2026NAMSNewAmsterdam Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026OLMAOlema Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$7.70M467.22N/AN/A$9.71 per share3.51NAMSNewAmsterdam Pharma$22.57M159.20N/AN/A$5.97 per share5.15OGNOrganon & Co.$6.22B0.57$5.80 per share2.31$2.89 per share4.64OLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$465.32M-$5.13N/AN/AN/A-2,747.18%-43.96%-39.61%8/6/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.79N/AN/AN/A-943.23%-26.49%-24.37%8/5/2026 (Estimated)OGNOrganon & Co.$187M$0.9314.413.901.243.99%99.95%6.22%8/4/2026 (Estimated)OLMAOlema Pharmaceuticals-$162.45M-$2.02N/AN/AN/AN/A-46.00%-41.22%8/10/2026 (Estimated)Latest OLMA, CRNX, NAMS, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52-$0.52N/A-$0.52N/AN/A5/7/2026Q1 2026CRNXCrinetics Pharmaceuticals-$1.22-$1.23-$0.01-$1.23$8.51 million$10.73 million5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46-$0.40+$0.06-$0.40$1.75 million$3.04 million4/30/2026Q1 2026OGNOrganon & Co.$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion3/31/2026Q1 2026NAMSNewAmsterdam PharmaN/A-$0.40N/A-$0.40N/A$3.04 million3/16/2026Q4 2025OLMAOlema Pharmaceuticals-$0.51-$0.50+$0.01-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.60%N/A8.60%N/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ALatest OLMA, CRNX, NAMS, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026OGNOrganon & Co.quarterly$0.020.6%5/11/20265/11/20266/11/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A18.6018.56NAMSNewAmsterdam PharmaN/A9.769.76OGNOrganon & Co.9.471.971.42OLMAOlema Pharmaceuticals0.0110.8810.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%NAMSNewAmsterdam Pharma89.89%OGNOrganon & Co.77.43%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals3.80%NAMSNewAmsterdam Pharma12.74%OGNOrganon & Co.1.62%OLMAOlema Pharmaceuticals12.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals210105.44 million101.43 millionOptionableNAMSNewAmsterdam Pharma4116.90 million102.01 millionOptionableOGNOrganon & Co.10,000262.60 million258.35 millionNot OptionableOLMAOlema Pharmaceuticals7087.35 million76.38 millionOptionableOLMA, CRNX, NAMS, and OGN HeadlinesRecent News About These CompaniesLifeSci Capital Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)June 8 at 1:50 PM | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO) and Oculis Holding (OCS)June 8 at 1:50 PM | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA) and Agios Pharma (AGIO)June 4, 2026 | theglobeandmail.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2026 | globenewswire.comOlema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration ...May 26, 2026 | markets.businessinsider.comOlema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate CancerMay 26, 2026 | globenewswire.comOlema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation GapMay 25, 2026 | finance.yahoo.comOlema Highlights Encouraging OP-3136 Phase 1 Oncology ResultsMay 22, 2026 | theglobeandmail.comOlema Oncology sees early hope as cancer drug shows tumor shrinkage in phase 1 studyMay 22, 2026 | msn.comOlema Pharmaceuticals Reports Promising Initial Data for OP-3136 in Phase 1 Study Evaluating KAT6 Inhibitor for Advanced Solid TumorsMay 21, 2026 | quiverquant.comQOlema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual MeetingMay 21, 2026 | globenewswire.comLifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)May 19, 2026 | theglobeandmail.comOlema Oncology to Participate in Upcoming Investor ConferencesMay 19, 2026 | globenewswire.comOlema: The Market Overreacted To Roche's SERD FailureMay 15, 2026 | seekingalpha.comOlema Oncology Reports First Quarter 2026 Financial and Operating ResultsMay 12, 2026 | markets.businessinsider.comOlema Pharmaceuticals inc Ordinary Shares OLMAMay 10, 2026 | morningstar.comMAssessing Olema Pharmaceuticals (OLMA) Valuation After Adding Dr. Prakash Raman To The BoardMay 10, 2026 | finance.yahoo.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | globenewswire.comOlema Pharmaceuticals Adds Veteran Director to Support GrowthApril 29, 2026 | tipranks.comOlema Oncology Appoints Prakash Raman, Ph.D., to Board of DirectorsApril 29, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOLMA, CRNX, NAMS, and OGN Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$34.12 +0.64 (+1.91%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.NewAmsterdam Pharma NASDAQ:NAMS$30.73 -0.22 (-0.71%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Organon & Co. NYSE:OGN$13.40 +0.02 (+0.11%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Olema Pharmaceuticals NASDAQ:OLMA$10.31 +0.35 (+3.51%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Walmart's No. 2 Ranking Hides a Digital Transformation Story AirJoule Technologies: A Cool Shot at a Multibagger Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
